1.
Sismondo S: Corporate disguises in medical science: dodging the interest repertoire. Bull Sci Technol Soc 2011;31:482-492.
2.
Spielmans GI, Parry PI: From evidence-based medicine to marketing-based medicine: evidence from internal industry documents. J Bioeth Inq 2010;7:13-29.
3.
Matheson A: The disposable author: how pharmaceutical marketing is embraced within medicine's scholarly literature. Hastings Cent Rep 2016;46:31-37.
4.
von Elm E, Poglia G, Walder B, Tramèr MR: Different patterns of duplicate publication: an analysis of articles used in systematic reviews. JAMA 2004;291:974-980.
5.
Spielmans GI, Biehn TL, Sawrey DL: A case study of salami slicing: pooled analyses of duloxetine for depression. Psychother Psychosom 2010;79:97-106.
6.
Pae C-U, Seo H-J, Lee BC, Seok J-H, Jeon HJ, Paik J-W, Kwak K-P, Ham B-J, Han C, Lee S-J: A meta-analysis comparing open-label versus placebo-controlled clinical trials for aripiprazole augmentation in the treatment of major depressive disorder: lessons and promises. Psychiatry Investig 2014;11:371-379.
7.
Arbaizar B, Dierssen-Sotos T, Gómez-Acebo I, Llorca J: Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials. Gen Hosp Psychiatry 2009;31:478-483.
8.
Nelson JC, Rahman Z, Laubmeier KK, Eudicone JM, McQuade RD, Berman RM, Marcus RN, Baker RA, Sheehan JJ: Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy. CNS Spectr 2014;19:528-534.
9.
Casey DE, Laubmeier KK, Eudicone JM, Marcus R, Berman RM, Rahman Z, Sheehan J: Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy. Int J Clin Pract 2014;68:1301-1308.
10.
Nelson JC, Thase ME, Bellocchio EE, Rollin LM, Eudicone JM, McQuade RD, Marcus RN, Berman RM, Baker RA: Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. Int Clin Psychopharmacol 2012;27:125-133.
11.
Casey DE, Laubmeier KK, Marler SV, Forbes RA, Baker RA: Efficacy of adjunctive aripiprazole in major depressive disorder: a pooled response quartile analysis and the predictive value of week 2 early response. Prim Care Companion CNS Disord 2012;14:PCC.11m01251.
12.
Muzina DJ, Chambers JS, Camacho TA, Eudicone JM, Forbes RA, Berman RM, Baker RA: Adjunctive aripiprazole for depression: predictive value of early assessment. Am J Manag Care 2011;17:793-801.
13.
Fabian TJ, Cain ZJ, Ammerman D, Eudicone JM, Tang Y, Rollin LM, Forbes RA, Berman RM, Baker RA: Improvement in functional outcomes with adjunctive aripiprazole versus placebo in major depressive disorder: a pooled post hoc analysis of 3 short-term studies. Prim Care Companion CNS Disord 2012;14:PCC.12m01394.
14.
Thase ME, Trivedi MH, Nelson JC, Fava M, Swanink R, Tran Q-V, Pikalov A, Yang H, Carlson BX, Marcus RN, Berman RM: Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. Prim Care Companion J Clin Psychiatry 2008;10:440-447.
15.
Bauer M, Thase ME, Liu S, Earley W, Eriksson H: Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder. J Psychopharmacol 2015;29:565-574.
16.
Bauer M, El-Khalili N, Datto C, Szamosi J, Eriksson H: A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord 2010;127:19-30.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.